Liva Healthcare, a digital health coaching service, has secured £22.1 million in new funding from investors.
The London and Copenhagen based company said it will use the funding to further scale across Europe. Its digital health and lifestyle coaching tools are being used for chronic disease prevention and management, such as Type 2 diabetes, obesity, and heart diseases.
The company is working with 4 STPs; Derbyshire, Nottingham & Nottinghamshire, Northamptonshire, and Worcestershire and Herefordshire and its lifestyle coaching app is also used by Amgen, AXA Health, City of Copenhagen and Bupa Australia.
In October we spoke with Thomas Cooke, clinical services manager at Liva Healthcare, who explained the benefits of personalised healthcare: “Personalised health care, by nature, encourages an open dialogue between patient and practitioner. When engaged in that dialogue, patients are often encouraged to set their health goals and objectives with a healthcare professional. Treatment options and advice can then be tailored to each individual and changed to help keep them on track.”
“Whilst the healthcare system has historically had to focus on treating symptoms over preventative treatments, personalised healthcare poses a huge opportunity. If we can reduce the number of people with chronic conditions like Type 2 diabetes and heart disease by providing tailored advice, we can transform individuals lives and lessen the burden on the NHS.”
“Particularly for weight management, having regular coaching and advice can result in sustainable weight loss that is maintained after the programme ends. A personalised approach works.”
The company said the new funding enables them to innovate and grow ahead of a likely Series C in 2022.
André Sode, CEO of Liva Healthcare, added: “This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets.”
“COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
